Mycobacterium tuberculosis (Mtb) has an unexpected vulnerability that future drugs may be able to exploit, according to a study from researchers at Weill Cornell Medicine. Read Here.
top of page
Recent Posts
See AllPhumeza Tisile was treated for MDR-TB in 2010 and suffered severe side effects from the drug, kanamycin. Her experiences drove her to...
120
The WHO has released new guidelines for prophylactic TB treatments. Among the updates to the guidelines are adjusted dosage...
100
The TB-CAPT consortium released a new study recently that showed that the new Xpert MTB/XDR testing can provide signigificantly faster...
170
bottom of page
Comentários